Business
InMed Expands on Announcement of Cannabinol (CBN) Therapeutic Leadership with New Website Content and CEO Interview
InMed Expands on Announcement of Cannabinol (CBN) Therapeutic Leadership with New Website ...
About this update from Infield Minerals Corp
[{"type":"text","content":"\n\n\n\nInMed Expands on Announcement of Cannabinol (CBN) Therapeutic Leadership with New Website Content and CEO Interview\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nVANCOUVER, Jan. 21, 2020\n\n\n\nVANCOUVER, Jan. 21, 2020 /CNW/ - InMed Pharmaceuticals Inc. (\"InMed\" or the \"Company\") (TSX:IN; OTCQX:IMLFF), a clinical stage biopharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), today published additional information describing in detail its leading cannabinol-based therapeutics programs on its corporate website at www.inmedpharma.com. \n\n \n \n\n \n\"Having revealed cannabinol, or CBN, as the active pharmaceutical ingredient in InMed's lead product candidates INM-755 and INM-088, we have now provided additional information on the potential for CBN formulations to treat disease.\" commented InMed CEO, Eric A. Adams. \"The initiation of clinical trials with INM-755 is just one of several examples of the significant progress the InMed team has made in advancing our understanding of CBN's therapeutic benefits as well as advancing our biosynthesis program in recent months.\" \nDetails of InMed's progress and milestones can be found in InMed's 2020 CEO Letter to Shareholders at: InMed 2020 Shareholders Letter\nMr. Adams was also recently interviewed by Edison Research Analyst Maxim Jacobs on the topic of the therapeutic potential of CBN and InMed's development pipeline. That interview is available at: CEO Interview \nYesterday at the EB World Congress in London, UK, InMed's scientific team officially revealed CBN as the active pharmaceutical ingredient (API) in INM-755 while exhibiting preclinical data in support of the INM-755 program in EB. InMed's EB2020 scientific posters can be viewed here. \nCBN is one of several rare cannabinoids found in the cannabis plant at significantly lower levels relative to the more commonly known tetrahydrocannabinol (THC) and cannabidiol (CBD). Despite structural similarity and common origin...